Symbols

ABSI

Absci·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Consensus Rating "Strong Buy"

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ABSI

Absci Corporation

A drug and target discovery company that harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins

Industry

Biological Technology

Established Date

Listing Date

07/22/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

140

Fiscal Year Ends

12-31

Website

www.absci.com

Security Type

Common stock

Office address

18105 SE Mill Plain Blvd, Vancouver, WA 98683

Business

Introduction

Absci Corporation was incorporated as a limited liability company in Oregon in August 2011. The company is a clinical-stage biopharmaceutical company that develops differentiated antibody therapies using artificial intelligence native methods. Its lead drug candidate, ABS-201, is an anti-prolactin receptor antibody that is being developed for androgenic alopecia and endometriosis, and related clinical trials are ongoing and planned.

Company Financials

EPS

ABSI has released its 2025 Q4 earnings. EPS was reported at -0.2, versus the expected -0.18, missing expectations. The chart below visualizes how ABSI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ABSI has released its 2025 Q4 earnings report, with revenue of 650.00K, reflecting a YoY change of -2.26%, and net profit of -29.56M, showing a YoY change of -2.00%. The Sankey diagram below clearly presents ABSI's revenue sources and cost distribution.